Home

The firm

Team

Portfolio

Investors

GOVERNANCE

Connect

  • Loading stock data...

About Nordicus

Transforming Potential Into Value

Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market.

Founded in 1993 as Cardiotech International, Inc., Nordicus Partners Corporation has evolved into a leading U.S. publicly traded business accelerator and holding company dedicated to empowering Nordic life sciences companies to succeed in the U.S. market. Combining Nordic innovation with U.S. operational expertise, we create a distinct advantage in identifying, scaling, and exiting high-potential companies in high-growth markets with unmet medical needs.

Nordicus Partners advises and invests in Nordic and U.S. life sciences companies, leveraging a diverse team of American and Nordic professionals to deliver exceptional results. Our team, a dynamic blend of Nordic and American professionals, combines diverse perspectives and strategies to create value and drive success for both the companies we support and our investors.

Headquartered in the U.S. and publicly listed on the OTCQB Market under the ticker symbol “NORD,” Nordicus Partners is strategically structured to maximize shareholder value. 

The NORDICUS Profile

We are targeting transformative and scalable opportunities, eyeing Nordic and U.S. life sciences companies aiming to make a significant impact, but is seeking a companion that can provide optimal conditions for innovators to flourish and getting established on the U.S. market.

Life Sciences

Kim Mücke

Member, Board of Directors

Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.

Andrew Ritter

Member, Board of Directors

Mr. Ritter is a seasoned healthcare executive with over two decades of leadership experience across biotechnology, digital health, and other healthcare technologies. He has successfully led multiple company exits, taken a company public on NASDAQ, and advised leading private equity and venture capital firms throughout the investment lifecycle.

He began his career as the founder and CEO of Ritter Pharmaceuticals, a microbiome-based biotech company. Over 17 years, he advanced the company from early-stage development through Phase III clinical trials, led its IPO onto the NASDAQ, and later merged the company with QualigenTherapeutics. Following that success, Mr. Ritter led a turnaround and successful exit of Docbot, an AI-driven MedTech company. He is currently an Entrepreneur in Residence at Khosla Ventures, and serves as CEO of portfolio company Cairns Health, an AI-powered remote care solutions to support Home and Senior Care.

He has also served as a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth. Mr. Ritter holds a B.A. in Political Science from the University of Southern California and an M.B.A. from the Wharton School of the University of Pennsylvania.